Literature DB >> 21303833

Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (I): catastrophic APS, APS nephropathy and heart valve lesions.

R Cervera1, M G Tektonidou, G Espinosa, A R Cabral, E B González, D Erkan, S Vadya, H E Adrogué, M Solomon, G Zandman-Goddard, Y Shoenfeld.   

Abstract

The objectives of the 'Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations' were to assess the clinical utility of the international consensus statement on classification criteria and treatment guidelines for the catastrophic APS, to identify and grade the studies that analyse the relationship between the antiphospholipid antibodies and the non-criteria APS manifestations and to present the current evidence regarding the accuracy of these non-criteria APS manifestations for the detection of patients with APS. This article summarizes the studies analysed on the catastrophic APS, APS nephropathy and heart valve lesions, and presents the recommendations elaborated by the Task Force after this analysis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21303833     DOI: 10.1177/0961203310395051

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  17 in total

Review 1.  Difficult clinical situations in the antiphospholipid syndrome.

Authors:  Renata Ferreira Rosa; Michelle Remião Ugolini-Lopes; Audrey Krüse Zeinad-Valim; Elbio D'Amico; Danieli Andrade
Journal:  Curr Rheumatol Rep       Date:  2015-04       Impact factor: 4.592

Review 2.  Renal involvement in antiphospholipid syndrome.

Authors:  Francisco Vileimar Andrade de Azevedo; Diego Germano Maia; Jozelio Freire de Carvalho; Carlos Ewerton Maia Rodrigues
Journal:  Rheumatol Int       Date:  2018-05-05       Impact factor: 2.631

Review 3.  Renal involvement in antiphospholipid syndrome.

Authors:  Guillermo J Pons-Estel; Ricard Cervera
Journal:  Curr Rheumatol Rep       Date:  2014-02       Impact factor: 4.592

4.  Autoantibodies to types I and IV collagen and heart valve disease in systemic lupus erythematosus/antiphospholipid syndrome.

Authors:  José Pardos-Gea; Josefina Cortés-Hernández; Jesus Castro-Marrero; Eva Balada; José Ordi-Ros
Journal:  Clin Rheumatol       Date:  2017-03-10       Impact factor: 2.980

5.  Definition and treatment approach of non-criteria clinical manifestations of antiphospholipid syndrome.

Authors:  Ayten Yazıcı
Journal:  Eur J Rheumatol       Date:  2020-10

Review 6.  Valvular heart disease in antiphospholipid syndrome.

Authors:  Stéphane Zuily; Olivier Huttin; Shirine Mohamed; Pierre-Yves Marie; Christine Selton-Suty; Denis Wahl
Journal:  Curr Rheumatol Rep       Date:  2013-04       Impact factor: 4.592

Review 7.  Use of eculizumab in a systemic lupus erythemathosus patient presenting thrombotic microangiopathy and heterozygous deletion in CFHR1-CFHR3. A case report and systematic review.

Authors:  Maria Izabel de Holanda; Luis Cristóvão Pôrto; Teresa Wagner; Luis Fernando Christiani; Lilian M P Palma
Journal:  Clin Rheumatol       Date:  2017-09-13       Impact factor: 2.980

8.  Antiphospholipid syndrome nephropathy (APSN) in patients with lupus nephritis: a retrospective clinical and renal pathology study.

Authors:  Gian Luca Erre; Luisanna Bosincu; Rossana Faedda; Patrizia Fenu; Antonio Masala; Marcella Sanna; Loredana Taras; Maria Giovanna Longu; Marco Piras; Giovanni Soro; Andrea Ercole Satta; Giuseppe Passiu
Journal:  Rheumatol Int       Date:  2014-04       Impact factor: 2.631

Review 9.  Defective complement inhibitory function predisposes to renal disease.

Authors:  Anuja Java; John Atkinson; Jane Salmon
Journal:  Annu Rev Med       Date:  2012-11-01       Impact factor: 13.739

Review 10.  Renal involvement in antiphospholipid syndrome.

Authors:  Savino Sciascia; Maria José Cuadrado; Munther Khamashta; Dario Roccatello
Journal:  Nat Rev Nephrol       Date:  2014-03-18       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.